Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4O2Z7)

Drug Name
Cyclophosphamide Drug Info
Synonyms
ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
2907
ChEBI ID
CHEMBL88
CAS Number
CAS 50-18-0
TTD Drug ID
D0CT9C
VARIDT Drug ID
DR00425
INTEDE Drug ID
DR0391
ACDINA Drug ID
D00157

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mismatch repair 1.95 3.69e-2 22/23 (95.65%) RFC2;EXO1;PCNA;...
DNA replication 1.88 2.30e-2 34/36 (94.44%) FEN1;RFC2;MCM2;...
Cell cycle 1.85 2.15e-2 110/124 (88.71%) CCNB2;ORC1;CCNE2;...
Proteasome 1.85 1.61e-2 44/46 (95.65%) PSMB8;PSMA6;PSMB2;...
NF-kappa B signaling pathway -1.81 4.81e-2 90/104 (86.54%) BCL10;ZAP70;TNF;...
Rheumatoid arthritis -1.83 3.92e-2 78/93 (83.87%) ATP6V0C;MMP3;HLA-DOB;...
Th1 and Th2 cell differentiation -1.87 3.74e-2 80/92 (86.96%) HLA-DOB;STAT4;CD247;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 20uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 20uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12.5uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 20uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H